Clinical characteristics, diagnostic strategies, and advances in grading criteria for tubercular uveitis

doi:10.19982/j.issn.1000-6621.20250196

Abstract

Abstract:

Tubercular uveitis (TBU) is a prevalent type of extrapulmonary tuberculosis, accounts for 0.2% to 32% of uveitis globally and approximately 0.7%-4% in China. Early diagnosis and standardized treatment of TBU can lead to favorable outcomes. However, due to the lack of reliable diagnostic methods, high clinical heterogeneity, and significant diagnostic delays (averaging 11 months), the actual incidence of TBU is likely underestimated. Hence, this article provides a systematic review of the clinical characteristics, classification, diagnostic criteria, and recent advances in immunological, molecular biological, and pathological diagnostic methods for TBU. By integrating evidence from recent studies, this article aims to assist tuberculosis specialists, pulmonologists, and ophthalmologists in promoting the early and standardized diagnosis of TBU.

Key words: Uveitis, Tuberculosis, ocular, Disease attributes, Molecular diagnostic techniques, Review literature as topic

CLC Number:

R52
R773.3

Lai Xiaoyu, Duan Hongfei, Chen Xunxun, Guo Huixin, Liao Qinghua, Chen Qian, Liang Dan. Clinical characteristics, diagnostic strategies, and advances in grading criteria for tubercular uveitis[J]. Chinese Journal of Antituberculosis, 2025, 47(9): 1204-1211. doi: 10.19982/j.issn.1000-6621.20250196

References 53

[1]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[2]	Agrawal R, Gunasekeran DV, Grant R, et al. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol, 2017, 135(12):1318-1327. doi:10.1001/jamaophthalmol.2017.4485. pmid: 29075752
[3]	Testi I, Agrawal R, Mahajan S, et al. Tubercular Uveitis: Nuggets from Collaborative Ocular Tuberculosis Study (COTS)-1. Ocul Immunol Inflamm, 2020, 28(sup1):8-16. doi:10.1080/09273948.2019.1646774.
[4]	Betzler BK, Gupta V, Agrawal R. Clinics of ocular tuberculosis: A review. Clin Exp Ophthalmol, 2021, 49(2): 146-160. doi:10.1111/ceo.13847. pmid: 33429468
[5]	Alli HD, Ally N, Mayet I, et al. Global prevalence and clinical outcomes of tubercular uveitis: a systematic review and meta-analysis. Surv Ophthalmol, 2022, 67(3):770-792. doi:10.1016/j.survophthal.2021.10.001.
[6]	Kotake S, Furudate N, Sasamoto Y, et al. Characteristics of endogenous uveitis in Hokkaido, Japan. Graefes Arch Clin Exp Ophthalmol, 1997, 235(1):5-9. doi:10.1007/BF01007830.
[7]	Win MZA, Win T, Myint S, et al. Epidemiology of Uveitis in a Tertiary Eye Center in Myanmar. Ocul Immunol Inflamm, 2017, 25(sup1):S69-S74. doi:10.3109/09273948.2015.1133839.
[8]	Abrahams IW, Jiang YQ. Ophthalmology in China. Endogenous uveitis in a Chinese ophthalmological clinic. Arch Ophthalmol, 1986, 104(3):444-446. doi:10.1001/archopht.1986.01050150146047.
[9]	Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res, 2005, 30 (11): 943-948. doi:10.1080/02713680500263606. pmid: 16282128
[10]	Shirley K, Dowlut S, Silvestri J, et al. Presumed ocular tuberculosis in the United Kingdom: a British Ophthalmological Surveillance Unit (BOSU) study. EYE, 2020, 34(5):890-897. doi:10.1038/s41433-019-0748-9.
[11]	Abdisamadov A, Tursunov O. Ocular tuberculosis epidemiology, clinic features and diagnosis:A brief review. Tuberculosis (Edinb), 2020, 124:101963. doi:10.1016/j.tube.2020.101963.
[12]	Agrawal R, Agarwal A, Jabs DA, et al. Standardization of Nomenclature for Ocular Tuberculosis-Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop. Ocul Immunol Inflamm, 2020, 28 (sup1): 74-84. doi:10.1080/09273948.2019.1653933.
[13]	Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol, 2005, 140 (3):509-516. doi:10.1016/j.ajo.2005.03.057. pmid: 16196117
[14]	彭晓燕, 毛羽. 结核性葡萄膜炎诊治困境及对策. 眼科, 2019, 28(5):325-327. doi:10.13281/j.cnki.issn.1004-4469.2019.05.002.
[15]	段鸿飞, 陶勇. 《眼内结核诊断规范》团体标准解读. 中国防痨杂志, 2025, 47(3):258-261. doi:10.19982/j.issn.1000-6621.20240572.
[16]	Testi I, Agrawal R, Mehta S, et al. Ocular tuberculosis: Where are we today?. Indian J Ophthalmol, 2020, 68(9):1808-1817. doi:10.4103/ijo.IJO_1451_20. pmid: 32823397
[17]	Kon OM, Beare N, Connell D, et al. BTS clinical statement for the diagnosis and management of ocular tuberculosis. BMJ Open Respir Res, 2022, 9(1):e001225. doi:10.1136/bmjresp-2022-001225.
[18]	Agarwal A, Aggarwal K, Gupta V. Infectious uveitis: an Asian perspective. Eye (Lond), 2019, 33(1):50-65. doi:10.1038/s41433-018-0224-y.
[19]	Gunasekeran DV, Agrawal R, Agarwal A, et al. The Colla-borative Ocular Tuberculosis Study (Cots) -1: A Multinational Review of 251 Patients With Tubercular Retinal Vasculitis. Retina, 2019, 39(8):1623-1630. doi:10.1097/IAE.0000000000002194. pmid: 29697588
[20]	Kaza H, Tyagi M, Pathengay A, et al. Clinical Predictors Of Tubercular Retinal Vasculitis In A High-Endemic Country. Retina, 2021, 41(2):438-444. doi:10.1097/IAE.0000000000002829.
[21]	Gonzalez Martinez OG, Villegas VM, Oliver AL, et al. Adjuvant Intravitreal Bevacizumab for Retinal Neovascularization in Eales’ Disease Associated With Latent Mycobacterium Tuberculosis. Cureus, 2023, 15(6): e41003. doi:10.7759/cureus.41003.
[22]	Lou SM, Montgomery PA, Larkin KL, et al. Diagnosis and treatment for ocular tuberculosis among uveitis specialists: the international perspective. Ocul Immunol Inflamm, 2015, 23(1): 32-39. doi:10.3109/09273948.2014.994784. pmid: 25615808
[23]	Lin CJ, Hsia NY, Hwang DK, et al. Clinical Manifestations and Outcomes of Tubercular Uveitis in Taiwan-A Ten-Year Multicenter Retrospective Study. Medicina (Kaunas), 2022, 58(3):376. doi:10.3390/medicina58030376.
[24]	中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识. 中国防痨杂志, 2021, 43(9): 874-878. doi:10.3969/j.issn.1000-6621.2021.09.004.
[25]	中华医学会结核病学分会. 结核分枝杆菌γ-干扰素释放试验及临床应用专家意见(2021年版). 中华结核和呼吸杂志, 2022, 45(2): 143-150. doi:10.3760/cma.j.cn112147-20211110-00794.
[26]	Ang M, Wong WL, Kiew SY, et al. Prospective head-to-head study comparing 2 commercial interferon gamma release assays for the diagnosis of tuberculous uveitis. Am J Ophthalmol, 2014, 157(6):1306-1314.e4. doi:10.1016/j.ajo.2014.01.031. pmid: 24508163
[27]	Ang M, Wong W, Ngan CCL, et al. Interferon-gamma release assay as a diagnostic test for tuberculosis-associated uveitis. Eye (Lond), 2012, 26(5): 658-665. doi:10.1038/eye.2012.1.
[28]	Chung CY, Li KKW. The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region. Int Ophthalmol, 2017, 38 (6): 2273-2282. doi:10.1007/s10792-017-0716-y.
[29]	Tomkins-Netzer O, Leong BCS, Zhang X, et al. Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis. Am J Ophthalmol, 2018, 190:164-170. doi:10.1016/j.ajo.2018.03.032. pmid: 29604284
[30]	Fernández-Zamora Y, Finamor LP, Silva LMP, et al. Role of Interferon-Gamma Release Assay for the Diagnosis and Clinical Follow up in Ocular Tuberculosis. Ocul Immunol Inflamm, 2022, 31(2):304-311. doi:10.1080/09273948.2022.2027459.
[31]	Pourakbari B, Mamishi S, Benvari S, et al. Can Interferon-γ Release Assays Be Useful for Monitoring the Response to Anti-tuberculosis Treatment?: A Systematic Review and Meta-analysis. Arch Immunol Ther Ex, 2020, 68(6):471-482. doi:10.1007/s00005-020-00568-4.
[32]	Ludi Z, Sule AA, Samy RP, et al. Diagnosis and biomarkers for ocular tuberculosis: From the present into the future. Theranostics, 2023, 13(7): 2088-2113. doi:10.7150/thno.81488. pmid: 37153734
[33]	程晓, 陈哲, 焦雪峰, 等. 重组结核杆菌融合蛋白(EC)用于诊断结核分枝杆菌感染的有效性和安全性系统评价. 中国防痨杂志, 2022, 44(9):917-926. doi:10.19982/j.issn.1000-6621.20220253.
[34]	Ireni S, Mooss VS, Kelgaonkar A, et al. Tubercular Serpiginous-Like Choroiditis in Patients with Negative TB-Immunoreactivity Tests. Ocul Immunol Inflamm, 2024, 32(8): 1549-1555. doi:10.1080/09273948.2023.2258399.
[35]	Agrawal R, Testi I, Bodaghi B, et al. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis. Ophthalmology, 2021, 128(2): 277-287. doi:10.1016/j.ophtha.2020.06.052. pmid: 32603726
[36]	Ganesh SK, Roopleen, Biswas J, et al. Role of high-resolution computerized tomography (HRCT) of the chest in granulomatous uveitis: a tertiary uveitis clinic experience from India. Ocul Immunol Inflamm, 2011, 19(1): 51-57. doi:10.3109/09273948.2010.525680. pmid: 21250925
[37]	Anshukita A, Dhanurekha L, Anand AR, et al. Polymerase Chain Reaction for Detection of Mycobacterium tuberculosis in Granulomatous Anterior Uveitis-An Analysis of 51 Eyes. Ocul Immunol Inflamm, 2023, 33(3):457-462. doi:10.1080/09273948.2024.2420661.
[38]	Sharma K, Sharma M, Ayyadurai N, et al. Comparative Evaluation of GeneXpert MTB/RIF Ultra and GeneXpert MTB/RIF for Detecting Tuberculosis and Identifying Rifampicin Resistance in Pars Plana Vitrectomy Samples of Patients with Ocular Tuberculosis. Ocul Immunol Inflamm, 2023, 31(5): 914-920. doi:10.1080/09273948.2022.2064880.
[39]	Xu H, Xu M, Chen F, et al. Detection of Mycobacterium tuberculosis DNA in intraocular fluid of 11 suspected tuberculous uveitis patients by multiplex PCR. BMC Ophthalmol, 2023, 23(1):7. doi:10.1186/s12886-023-02588-2.
[40]	Sharma K, Sharma M, Ayyadurai N, et al. Evaluating Truenat Assay for the Diagnosis of Ocular Tuberculosis and Detection of Drug Resistance. Ocul Immunol Inflamm, 2023, 32(6): 976-982. doi:10.1080/09273948.2023.2170888.
[41]	Zhang YK, Guan Y, Zhao J, et al. Diagnosis of tuberculous uveitis by the macrogenome of intraocular fluid: A case report and review of the literature. World J Clin Cases, 2023, 11(14): 3248-3255. doi:10.12998/wjcc.v11.i14.3248.
[42]	La Distia Nora R, Putera I, Khalisha DF, et al. The diagnostic value of polymerase chain reaction for ocular tuberculosis diagnosis in relation to antitubercular therapy response: a meta-analysis. Int J Infect Dis, 2021, 110:394-402. doi:10.1016/j.ijid.2021.07.075. pmid: 34364996
[43]	Basu S, Elkington P, Rao NA. Pathogenesis of ocular tuberculosis: New observations and future directions. Tuberculosis (Edinb), 2020, 124:101961. doi:10.1016/j.tube.2020.101961.
[44]	Song JH, Koreishi AF, Goldstein DA. Tuberculous Uveitis Presenting with a Bullous Exudative Retinal Detachment: A Case Report and Systematic Literature Review. Ocul Immunol Inflamm, 2019, 27(6):985-991. doi:10.1080/09273948.2018.1485958.
[45]	Raina UK, Tuli D, Arora R, et al. Tubercular endophthalmitis simulating retinoblastoma. Am J Ophthalmol, 2000, 130(6): 843-845. doi:10.1016/s0002-9394(00)00646-2. pmid: 11124314
[46]	Wroblewski KJ, Hidayat AA, Neafie RC, et al. Ocular tuberculosis: a clinicopathologic and molecular study. Ophthalmology, 2011, 118 (4): 772-777. doi:10.1016/j.ophtha.2010.08.011. pmid: 21055814
[47]	Albert DM, Raven ML. Ocular Tuberculosis. Microbiol Spectr, 2016, 4(6):10.1128/microbiolspec.TNMI7-0001-2016. doi:10.1128/microbiolspec.TNMI7-0001-2016.
[48]	Helm CJ, Holland GN. Ocular tuberculosis. Surv Ophthalmol, 1993, 38(3): 229-256. doi:10.1016/0039-6257(93)90076-j. pmid: 8310395
[49]	Basu S, Wakefield D, Biswas J, et al. Pathogenesis and Pathology of Intraocular Tuberculosis. Ocul Immunol Inflamm, 2015, 23(4): 353-357. doi:10.3109/09273948.2015.1056536. pmid: 29265968
[50]	Kawali A, Emerson GG, Naik NK, et al. Clinicopathologic Features of Tuberculous Serpiginous-like Choroiditis. JAMA Ophthalmol, 2018, 136(2):219-221. doi:10.1001/jamaophthalmol.2017.5791. pmid: 29270629
[51]	Burkholder BM, Jabs DA. Uveitis for the non-ophthalmologist. BMJ, 2021, 372:m4979. doi:10.1136/bmj.m4979.
[52]	Lee JH, Agarwal A, Mahendradas P, et al. Viral posterior uveitis. Surv Ophthalmol, 2017, 62(4): 404-445. doi:10.1016/j.survophthal.2016.12.008. pmid: 28012878
[53]	Sève P, Cacoub P, Bodaghi B, et al. Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. Autoimmun Rev, 2017, 16(12): 1254-1264. doi:10.1016/j.autrev.2017.10.010. pmid: 29037906